WIDE Trial

Cross-source consensus on WIDE Trial from 1 sources and 5 claims.

1 sources · 5 claims

Comparisons

Other

Highlighted claims

The WIDE control arm receives robotic minimally invasive Ivor Lewis oesophagectomy without any pyloric intervention. — Intraoperative endoscopic pylorus dilatation during minimally invasive Ivor Lewis oesophagectomy to prevent delayed gastric conduit emptying (DGCE): protocol for the WIDE randomised controlled trial
The WIDE trial is a single-centre, investigator-initiated, double-blind randomised controlled superiority trial with 1:1 allocation. — Intraoperative endoscopic pylorus dilatation during minimally invasive Ivor Lewis oesophagectomy to prevent delayed gastric conduit emptying (DGCE): protocol for the WIDE randomised controlled trial
Eligible patients must be at least 18 years old, have confirmed oesophageal or gastro-oesophageal junction carcinoma, be planned for curative Ivor Lewis oesophagectomy, and be able to consent. — Intraoperative endoscopic pylorus dilatation during minimally invasive Ivor Lewis oesophagectomy to prevent delayed gastric conduit emptying (DGCE): protocol for the WIDE randomised controlled trial
The WIDE trial is conducted at Clarunis in Basel, Switzerland, a high-volume referral centre performing about 50–70 oesophagectomies per year. — Intraoperative endoscopic pylorus dilatation during minimally invasive Ivor Lewis oesophagectomy to prevent delayed gastric conduit emptying (DGCE): protocol for the WIDE randomised controlled trial
Recruitment for WIDE is planned over about 30 months, starting in December 2025 and expected to complete around January 2028. — Intraoperative endoscopic pylorus dilatation during minimally invasive Ivor Lewis oesophagectomy to prevent delayed gastric conduit emptying (DGCE): protocol for the WIDE randomised controlled trial